Literature DB >> 24502246

Disopyramide and mianserin intoxication: a unique fatal case--review of the literature.

Le Blanc-Louvry Isabelle1, Franck Clarot, Emmanuelle Vaz, Jean Pierre Goullé, Bernard Proust.   

Abstract

Lethal occurrence is exceptional after disopyramide or mianserin poisoning. A case of intentional lethal intoxication with these drugs was reported, as well as a review of the literature. Pre- and postmortem blood concentrations of disopyramide or mianserin were assessed in a woman who died from acute cardiac failure after ingestion. The premortem blood concentration of disopyramide alone was considered lethal, and a toxic premortem concentration of mianserin was observed that may have increased cardiovascular failure induced by disopyramide because the metabolism of both drugs is mediated via cytochrome P450. Moreover, it was shown that the postmortem redistribution of disopyramide was limited, as pre- and postmortem concentrations were 48 and 65 mg/L, respectively. As regards mianserin, redistribution was observed after death with pre- and portmortem concentrations at 0.23 and 0.79 mg/L, respectively. This case illustrates that if postmortem blood concentration of disopyramide is known, the premortem concentration can be deduced.
© 2014 American Academy of Forensic Sciences.

Entities:  

Keywords:  autopsy; disopyramide; forensic sciences; forensic toxicology; lethal issue; mianserin; redistribution

Mesh:

Substances:

Year:  2014        PMID: 24502246     DOI: 10.1111/1556-4029.12392

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  1 in total

1.  Higher efficacy of direct hemoperfusion using coated activated-charcoal column for disopyramide poisoning: A case report.

Authors:  Shigekazu Iguchi; Naotaka Yamaguchi; Hiroki Takami; Takayuki Komatsu; Hirokazu Ookubo; Hajime Sekii; Kenji Inoue; Shinya Okazaki; Iwao Okai; Sonomi Maruyama; Tomohisa Nomura; Manabu Sugita
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.